Reaxys Announces Winners of the 2013 Reaxys PhD Prize

            Reaxys Announces Winners of the 2013 Reaxys PhD Prize

  PR Newswire

  NEUCHÂTEL, Switzerland, July 3, 2013

NEUCHÂTEL, Switzerland, July 3, 2013 /PRNewswire/ --

   The Reaxys PhD Prize awards original and innovative research in organic,
                    organometallic and inorganic chemistry

Reaxys ® , a unique workflow solution for chemistry research, has today
announced the winners of the 2013 Reaxys PhD Prize . Awarding innovative and
original research in organic, organometallic and inorganic chemistry, the
Reaxys PhD Prize celebrates top research conducted by leading young chemists
across the globe.

The 2013 Reaxys PhD Prize Winners are:

  *Martin Donakowski from the Poeppelmeier group at Northwestern University,
    USA
  *Max Hansmann from the Hashmi group at University of Heidelberg, Germany
  *Johannes Heppekausen from the Fürstner group at the Max-Planck Institute,
    Mülheim, Germany

The winners were selected from 45 finalists by the Chairs of the Reaxys PhD
Prize's review board: Professors Tony Barrett (Imperial College London, UK),
Eiichi Nakamura (University of Tokyo, Japan), Gerard Parkin (Columbia
University, New York, USA), Martin Jansen (Max-Planck Institute, Stuttgart,
Germany), Barry Trost (Stanford University, USA) and Henry Wong (Chinese
University Hong Kong, Hong Kong).

"Since its inception in 2010 there has been an ever increasing number of
superb applications for the Reaxys PhD Prize. Whilst this has provided the
review board with an immense task of selecting the top three candidates, their
efforts have been rewarded by the delight of reading such elegant creative
synthetic chemistry," said Professor Barrett. "There is no doubt that the
future global strength of chemistry is securely based on a cohort of
outstanding young scientists, who are all a credit to our subject and to their
own universities. I look forward to personally interacting with members of the
Reaxys Prize Club, a most select society."

This year a record of 581 submissions were received from nearly 400
universities across the globe. Submissions consisted of a representative,
peer-reviewed published research paper accompanied by a PhD's supervisor
recommendation letter and CV. Entries were closely scrutinized by a review
board of over 100 international chemists from academia and industry. The
reviewers judged the entries for originality, innovation, importance to the
field, applicability, rigor of approach and publication quality.

The three winners and 42 remaining finalists have been invited to attend the
Reaxys Inspiring Chemistry Conference which will be held in Grindelwald,
Switzerland, September 22 - 24, 2013 where they will be given the opportunity
to present their research.

For more information about the Reaxys PhD Prize and Chemistry Conference go
to: http://inspiringchemistry.reaxys.com/phdprize ;
http://inspiringchemistry.reaxys.com/conference

For more information about Reaxys go to http://www.elsevier.com/reaxys

About Reaxys

Reaxys® is a workflow solution for research chemists. Offering a wealth of
experimentally validated information, Reaxys® combines reaction and substance
data in organic, organometallic, inorganic and physical chemistry with
synthesis planning. Researchers can get the information they need in a single
overview, from source publications carefully selected for their importance and
relevance to research chemists. Elsevier continues to engage with the
chemistry community to ensure that Reaxys® continues to reflect how chemists
think and work. For more information please visit Reaxys .

Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier
Properties SA and used under license.

About Reed Elsevier Properties SA

Reed Elsevier Properties SA is a centre of excellence within Reed Elsevier for
the management, development and protection of intellectual property. Reed
Elsevier Properties SA owns the PharmaPendium and Reaxys databases. Trademarks
including Reaxys®, PharmaPendium®, Targetinsights™, The Lancet® and World
Travel Market® are owned and protected by Reed Elsevier Properties SA and used
under licence.

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical
information products and services. The company works in partnership with the
global science and health communities to publish more than 2,000 journals,
including The Lancet and Cell , and close to 20,000 book titles, including
major reference works from Mosby and Saunders. Elsevier's online solutions
include ScienceDirect , Scopus , Reaxys , ClinicalKey and Mosby's Suite ,
which enhance the productivity of science and health professionals, and the
SciVal suite and MEDai's Pinpoint Review , which help research and health care
institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people
worldwide. The company is part of Reed Elsevier Group plc , a world leading
provider of professional information solutions. The group employs more than
30,000 people, including more than 15,000 in North America. Reed Elsevier
Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed
Elsevier NV. Their shares are traded on the London, Amsterdam and New York
Stock Exchanges using the following ticker symbols: London: REL; Amsterdam:
REN; New York: RUK and ENL.

Media contact Liz Griffioen Elsevier +31-20-485-2247 l.griffioen@elsevier.com
 
Press spacebar to pause and continue. Press esc to stop.